Compare CATO & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CATO | BNTC |
|---|---|---|
| Founded | 1946 | 1995 |
| Country | United States | United States |
| Employees | N/A | 24 |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.9M | 396.3M |
| IPO Year | 1994 | 2020 |
| Metric | CATO | BNTC |
|---|---|---|
| Price | $2.48 | $10.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $27.67 |
| AVG Volume (30 Days) | ★ 130.3K | 99.5K |
| Earning Date | 05-21-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.04 | 6.67 |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $653,812,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.77 | ★ N/A |
| Revenue Growth | ★ 0.62 | N/A |
| 52 Week Low | $2.30 | $9.85 |
| 52 Week High | $4.67 | $16.76 |
| Indicator | CATO | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 38.74 | 35.19 |
| Support Level | $2.30 | $10.04 |
| Resistance Level | $3.20 | $14.14 |
| Average True Range (ATR) | 0.09 | 0.65 |
| MACD | 0.02 | -0.17 |
| Stochastic Oscillator | 43.90 | 8.56 |
The Cato Corp seeks to offer quality fashion apparel and accessories at low prices every day, in junior/missy and plus sizes. The Cato concept's stores and e-commerce website feature a broad assortment of apparel and accessories, including dressy, career, and casual sportswear, dresses, coats, shoes, lingerie, costume jewelry, and handbags. Management believes the Company's success is dependent upon its ability to differentiate its stores from department stores, mass merchandise discount stores, and competing specialty stores. The key elements of the Company's business are: Merchandise Assortment, Value Pricing, Strip Shopping Center Location, Customer Service, Credit and Layaway Programs.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.